Agilent Board Chair Retires After 23 Years; Dow Wilson Takes Over
Event summary
- Koh Boon Hwee retired from Agilent’s board after 23 years, including 9 as chair, effective September 4, 2026.
- Dow R. Wilson, who joined the board in 2018, was elected as the new chair, also effective September 4, 2026.
- Glenn Boehnlein, former CFO of Stryker Corporation, was appointed to the board, bringing medical tech and finance expertise.
The big picture
Agilent’s board transition reflects a shift in governance leadership, with Dow Wilson taking over from Koh Boon Hwee, who brought deep Asia-Pacific expertise. The appointment of Glenn Boehnlein, a seasoned medical tech executive, signals a focus on financial strategy and operational excellence. The changes come as Agilent navigates a competitive landscape in analytical and clinical lab technologies, with $6.95 billion in revenue in fiscal 2025.
What we're watching
- Governance Dynamics
- How Dow Wilson’s leadership will influence Agilent’s strategic direction, particularly in the Asia-Pacific region.
- Financial Strategy
- Whether Glenn Boehnlein’s medical tech and finance expertise will drive operational improvements.
- Long-Term Value
- The pace at which Agilent can sustain growth under the new board leadership.